Evolent HealthvsMerck & Company

EVH and MRK stock compared: price, dividend, valuation and results, from SEC filings.

EVH

Evolent Health, Inc

$4.83

Value $539M

-1.43%
EVH's page

MRK

Merck & Company, Inc.

$144.46

Value $357B

-2.23%
MRK's page

Evolent Health (EVH) has a market value of $539M and Merck & Company (MRK) $357B. Over the last year, with dividends, EVH moved +15.6% and MRK +60.0%. Dividend yield: EVH none, MRK 2.35%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    EVH$539M

    MRK$357B

    MRK is 662 times EVH

  • Revenue, 12 months

    EVH$2.3B

    MRK$67.4B

    MRK is 29 times EVH

  • Net income, 12 months

    EVH-$508M

    MRK$2.5B

  • Operating margin

    EVH-18.6%

    MRK–

  • ROIC

    EVH-21.8%

    MRK3.9%

    25.7 points apart

  • P/E

    EVH–

    MRK145.6

  • Dividend yield

    EVH0.0%

    MRK2.4%

    2.4 points apart

  • 5-year return

    EVH-82.5%

    MRK+101.1%

    183.6 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

EVH-82.5%

MRK+101.1%

010020020222023202420252026
Returns by period
PeriodEVHWith dividendsMRKWith dividends
1 year since November 14, 2025+15.6%Price +15.6%+60.0%Price +55.5%
3 years since November 16, 2023-83.6%-45.3% a yearPrice -83.6%+55.2%+15.8% a yearPrice +41.6%
5 years since November 15, 2021-82.5%-29.4% a yearPrice -82.5%+101.1%+15.0% a yearPrice +72.6%
10 years since November 16, 2016-72.7%-12.2% a yearPrice -72.7%+228.0%+12.6% a yearPrice +141.7%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

EVHEvolent HealthMRKMerck & Company

Valuation

EVHMRK
Valuation
Price$4.83$144.46
Market value$539M$357B
Enterprise value (EV)$1.4B$401B
P/E–145.6
P/E, 5-year median–14.8
P/B1.58.0
EV/EBIT–84.3
Free cash flow yield6.8%4.1%

Results and growth

EVHMRK
Results and growth
Revenue, 12 months$2.3B$67.4B
Net income, 12 months-$508M$2.5B
Free cash flow, 12 months$37M$14.7B
Earnings per share, 12 months-$4.54$0.98
Revenue growth, year on year-26.6%1.3%
Revenue growth a year, past+15.2%over 5 years+9.4%over 5 years
EPS growth a year, past–+21.2%over 5 years

Margins and returns on capital

EVHMRK
Margins and returns on capital
Gross margin15.0%71.8%
Operating margin-18.6%–
Net margin-21.7%3.6%
ROIC-21.8%3.9%
ROE-105.3%5.2%

Balance sheet

EVHMRK
Balance sheet
Cash$148M$9.7B
Total debt$973M$53.8B
Net debt / EBITDA–5.7
Interest cover-6.2×2.4×

Dividends and buybacks

EVHMRK
Dividends and buybacks
Dividend yield–2.4%
Dividend per share, 12 months–$3.40
Dividend growth a year, past–+5.8%over 5 years
Buyback yield7.4%1.4%
Shareholder yield7.4%3.8%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: EVH or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, Evolent Health or Merck & Company?

By market value, Merck & Company ($357B) is about 662.4 times Evolent Health ($539M), at today's prices.

How did EVH and MRK stock do over the last 10 years?

Since November 16, 2016, EVH's price moved -72.7% and MRK's +141.7%. With dividends: EVH -72.7% (-12.2% a year), MRK +228.0% (+12.6% a year). Past returns do not predict future ones.

Which pays the higher dividend, EVH or MRK?

The dividend yield at today's price is none for Evolent Health and 2.35% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.

Which has the higher profit margins, Evolent Health or Merck & Company?

Over the last twelve months, the net margin was -21.7% for Evolent Health and 3.6% for Merck & Company, and the operating margin -18.6% and –. Revenue was $2.3B and $67.4B.

Which is the better investment, Evolent Health or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.